News
8
blog,paged,paged-4,bridge-core-1.0.4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-18.0.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their review of the interim analysis of the results from the phase I dosing part of the multicentre trial VB C-01. The two committees recommended continuation...

Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). Patients will receive...

The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015.   Dr. Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako AS, followed by Ostemeter AS...